Scarica l'app Stockscreener
1.19
0.42%
-0.01
Precedente Chiudi:
$1.18
Aprire:
$1.18
Volume 24 ore:
18,422
Relative Volume:
0.10
Capitalizzazione di mercato:
$27.02M
Reddito:
$950.10K
Utile/perdita netta:
$-16.69M
Rapporto P/E:
-1.4337
EPS:
-0.83
Flusso di cassa netto:
$-15.16M
1 W Prestazione:
-0.42%
1M Prestazione:
+6.82%
6M Prestazione:
+11.90%
1 anno Prestazione:
+0.43%
Intervallo 1D:
$1.16
$1.195
Intervallo di 1 settimana:
$1.09
$1.33
Portata 52W:
$0.86
$2.40
Femasys Inc Stock (FEMY) Company Profile
Nome
Femasys Inc
Settore
Industria
Telefono
770-500-3910
Indirizzo
3950 JOHNS CREEK COURT, SUWANEE
Confronta FEMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.19 | 27.02M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
587.89 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.27 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.28 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.53 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
329.05 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Femasys Inc Borsa (FEMY) Ultime notizie
Femasys gains approvals for infertility and diagnostic products in Israel - Yahoo Finance
Pap Test Market: Current Analysis and Forecast (2022-2028) - UnivDatos Market Insights
Femasys Announces Israeli Regulatory Approvals for - GlobeNewswire
Femasys announces notices of intention to grant for two new European patent applications - MSN
Femasys Announces Notices of Intention to Grant for Two New - GlobeNewswire
Game-Changing Birth Control Tech: Femasys Locks Down Crucial EU Patents for Non-Surgical Alternative - StockTitan
Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed - MSN
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Marketscreener.com
Femasys Announces Notice of Allowance for New U.S. Patent - GlobeNewswire
Femasys Secures Patent Protection for FemaSeed Fertility Treatment Through 2044 - StockTitan
Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC - Defense World
Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next? - Defense World
HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World
Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria
Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports
Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Issued New U.S. Patent for FemBloc Permanent Birth Control - MPO-mag
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
The 10 Best Booths from ASRM 2022 - Exhibitor Online
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Inc Azioni (FEMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):